PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(03): 151-154
DOI: 10.1055/s-0041-1727067
Original Article: Gastrointestinal Cancer

Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study

Deepa M. Joseph
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
,
Monica Irukulla Malik
2   Department of Radiation Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Jyothi Jonnadula
2   Department of Radiation Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Fayaz Ahmed
2   Department of Radiation Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Deepthi Valiyaveettil
2   Department of Radiation Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
› Institutsangaben Funding None.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Objective Neoadjuvant chemoradiation (CRT) using paclitaxel and carboplatin has significantly improved the survival rates in carcinoma esophagus, especially in squamous cell carcinoma (SCC). This regimen has not been adequately explored prospectively as a definitive CRT strategy. Our aim was to evaluate the efficacy, toxicity, and compliance to this regimen in a prospective setting in locally advanced esophageal SCC.

Materials and Methods Patients with locally advanced esophageal SCC were planned for definitive CRT by using weekly paclitaxel 50 mg/m2 and carboplatin area under curve 2 along with radical radiotherapy to a dose of 50.4 to 54 Gy. Treatment-related toxicity was assessed by using the common terminology criteria for Adverse Events Version 4.0, and the response was assessed by using endoscopy and computed tomography (CT) 4 to 6 weeks following CRT. The pathological response was documented for those who underwent surgery.

Results Fifteen patients were included in the study, and all patients completed the planned course of radiation. The median number of chemotherapy cycles received was four. In total, 66% of the patients had delay or interruptions in chemotherapy, mostly due to neutropenia, and 66% of the patients had a clinical complete response (CR). Four patients underwent definitive esophagectomy, and the histopathology revealed pathologic CR. Overall CR rate was 80%. The median overall survival was 14 months, and 1-year survival was 57%.

Conclusion Definitive CRT in esophageal SCC using weekly paclitaxel and carboplatin was relatively well tolerated with manageable toxicities and good clinical response rates. It may potentially represent a new standard of care as definitive therapy in the management of these tumors.

Keywords

esophageal squamous cell carcinoma - radical chemoradiation - weekly paclitaxel and carboplatin


Publikationsverlauf

Artikel online veröffentlicht:
04. September 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Ferlay J, Soerjomataram I, Dikshit R. et al Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
    CrossrefPubMedGoogle Scholar
  • 2 Shapiro J, van Lanschot JJ, Hulshof MCC. et al CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16 (09) 1090-1098
    CrossrefPubMedGoogle Scholar
  • 3 D’Amico TA. Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res 2007; 1 (05) 188-196
    PubMedGoogle Scholar
  • 4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66 (01) 7-30
    CrossrefPubMedGoogle Scholar
  • 5 Herskovic A, Martz K, al-Sarraf M. et al Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326 (24) 1593-1598
    CrossrefPubMedGoogle Scholar
  • 6 Herskovic A, Leichman L, Lattin P. et al Chemo/radiation with and without surgery in the thoracic esophagus: the Wayne State experience. Int J Radiat Oncol Biol Phys 1988; 15 (03) 655-662
    CrossrefPubMedGoogle Scholar
  • 7 Minsky BD, Pajak TF, Ginsberg RJ. et al INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20 (05) 1167-1174
    CrossrefPubMedGoogle Scholar
  • 8 Bedenne L, Michel P, Bouché O. et al Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25 (10) 1160-1168
    CrossrefPubMedGoogle Scholar
  • 9 Stahl M, Stuschke M, Lehmann N. et al Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23 (10) 2310-2317
    CrossrefPubMedGoogle Scholar
  • 10 Kim DW, Blanke CD, Wu H. et al Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2007; 67 (02) 397-404
    CrossrefPubMedGoogle Scholar
  • 11 Kelsey CR, Chino JP, Willett CG. et al Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys 2007; 69 (03) 770-776
    CrossrefPubMedGoogle Scholar
  • 12 Tepper J, Krasna MJ, Niedzwiecki D. et al Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26 (07) 1086-1092
    CrossrefPubMedGoogle Scholar
  • 13 Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8 (03) 226-234
    CrossrefPubMedGoogle Scholar
  • 14 Mariette C, Dahan L, Mornex F. et al Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32 (23) 2416-2422
    CrossrefPubMedGoogle Scholar
  • 15 Honing J, Smit JK, Muijs CT. et al A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014; 25 (03) 638-643
    CrossrefPubMedGoogle Scholar
  • 16 Haj Mohammad N, Hulshof MC, Bergman JJ. et al Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. BMC Cancer 2014; 14: 56
    CrossrefPubMedGoogle Scholar
  • 17 Ruppert BN, Watkins JM, Shirai K. et al Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010; 33 (04) 346-352
    CrossrefPubMedGoogle Scholar
  • 18 Noronha V, Prabhash K, Joshi A. et al Clinical outcome in definitive concurrent chemoradiation with weekly paclitaxel and carboplatin for locally advanced esophageal and junctional cancer. Oncol Res 2016; 23 (04) 183-195
    CrossrefPubMedGoogle Scholar